Target
CDK6
14 products, 14 indications
Indications
HR+/HER2- metastatic breast cancer (5 products)
glioblastoma (3 products)
Metastatic Castration-Resistant Prostate Cancer (3 products)
HR+/HER2- early-stage breast cancer (2 products)
HR-positive breast cancer (1 products)
NSCLC (1 products)
advanced acral lentiginous melanoma (1 products)
high grade serous ovarian carcinoma (1 products)
metastatic non-small cell lung cancer (1 products)
Stage III melanoma (1 products)
ER+HER2- breast cancer (1 products)
BRAF V600E Mutation-Positive Unresectable or Metastatic Melanoma (1 products)
Metastatic Cancer (1 products)
relapsed ER positive ovarian cancer or endometrial cancer (1 products)
Loading...
4 drugs
156 abstracts
Abstract
Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul National University Hospital, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Department of Hematology-Oncology,
Abstract
Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Alliance Statistics and Data Management Center, Mayo Clinic Rochester,
Abstract
CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer.Org: Massachusetts General Hospital Cancer Center and Harvard Medical School, Institut Català d’Oncologia–Bellvitge Institute for Biomedical Research, Studienpraxis Urologie, Asan Medical Center, Hospital Universitario Gregorio Marañón,
Abstract
Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).Org: Peter MacCallum Cancer Centre, Melbourne, Australia, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, UT Southwestern Simmons Comprehensive Cancer Center, Lifespan Cancer Institute, Legorreta Cancer Center at Brown University,
Abstract
A phase I/II trial of palbociclib, pembrolizumab, and endocrine therapy for patients with HR+/HER2- locally advanced or metastatic breast cancer (MBC): Clinical outcomes and stool microbial profiling.Org: City of Hope Comprehensive Cancer Center, Translational Genomics Research Institute (TGen North), Cedars-Sinai Medical Center,
Abstract
H3B-6545 + palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC).Org: Royal Marsden NHS Foundation Trust, Saint Luke's Cancer Institute, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarah Cannon Research Institute/Tennessee Oncology, Eisai,
Abstract
Characterization of molecular response and progression in patients with metastatic HR+/HER2- breast cancer receiving endocrine therapy and CDK4/6 inhibitors using a high-sensitivity tumor-informed assay.Org: Division of Medical Oncology & Hematology,
Abstract
Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study.Org: Memorial Sloan Kettering Cancer Center, University of Vermont Cancer Center, Université Libre de Bruxelles (ULB), Institut Jules Bordet, Université Libre de Bruxelles, Medical Oncology Department,
Abstract
Neoadjuvant dalpiciclib, exemestane, and goserelin in premenopausal women with HR-positive, HER2-negative breast cancer: A prospective, multicenter, randomized two-group, non-controlled phase 2 clinical trial.Org: Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Hemay Pharmaceutical, China National Biotec Group, Tianjian,
Abstract
Evaluating metrics of circulating tumor DNA response and progression using a high sensitivity tumor-agnostic assay in metastatic HR+/HER2- breast cancer receiving endocrine therapy and a CDK4/6-inhibitor.Org: Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Department of Medical Biophysics, University of Toronto,
Abstract
Abemaciclib dose escalation to maintain intensity (ADE-MI).Org: University of Illinois Hospital & Health Sciences System, University of Illinois Chicago, University of Illinois at Chicago, University of Illinois Chicago College of Pharmacy,
Abstract
A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009.Org: Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, MedStar Health, University of Pittsburgh School of Public Health, University of Pittsburgh Medical Center (UPMC),
Abstract
ECLECTIC: 18F-fluoroestradiol PET and circulating biomarkers to guide the choice of the second line therapy for ER+, HER2- metastatic breast cancer: A phase 3 trial.Org: Institut Curie, Saint Cloud, France, Paris and Saint Cloud, France, Centre Oscar Lambret, Lille University Hospital,
Abstract
Innovation of the first-line strategy optimized as abemaciclib with endocrine therapy based on the ESR1 mutation of ctDNA for patients with HR-positive HER2-negative advanced metastatic breast cancer (JBCRG-M08; AMBER study).Org: Osaka University Hospital, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Nagoya University Hospital,
Abstract
Implementing geriatric assessment for dose optimization of CDK 4/6 inhibitors in older breast cancer patients (IMPORTANT trial): A pragmatic randomized-controlled trial.Org: Örebro University Hospital, Santo Stefano Hospital, General Hospital of Patras St. Andrews, Akershus University Hospital (Ahus), Papageorgiou General Hospital,
Abstract
Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.Org: SOLTI Cancer Research Group, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Vall d’Hebron Institute of Oncology,
Abstract
Plasma mutational burden in PIK3CA and TP53 independently predicts early progression in patients with HR+/HER2- metastatic breast cancer (MBC) enrolled in the GEICAM/2014-12 FLIPPER trial.Org: Sysmex Inostics Gmbh, Sysmex Inostics, Inc., GEICAM Spanish Breast Cancer Group, Cancer Trials Ireland, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) ,
Abstract
ETHAN: A phase II study comparing different endocrine therapies for male breast cancer.Org: Dana-Farber Cancer Institute/Harvard Medical School, Mayo Clinic, Department of Biostatistics & Data Science, The University of North Carolina at Chapel Hill, The University of Texas MD Anderson Cancer Center,
Abstract
pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs. fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), in patients (pts) with estrogen receptor-positive (ER+), HER2– locally advanced/metastatic BC (LA/mBC) with resistance to prior adjuvant (adj) endocrine therapy (ET).Org: Winship Cancer Institute of Emory University, Dana-Farber Cancer Institute, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, University Hospital Erlangen, Hospital Alemán,
Abstract
Genomic alterations in DNA damage response (DDR) genes in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG): Biomarker results from TROPICS-02 study.Org: David Geffen School of Medicine at UCLA, University of California Irvine, Jonsson Comprehensive Cancer Center, Los Angeles, CA, Gilead Sciences, Inc.,
Abstract
A phase II trial comparing dalpiciclib in combination with letrozole versus standard chemotherapy as neoadjuvant therapy in patients with high-risk HR- positive HER-2 negative breast cancer: DARLING-02.Org: The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Affiliated Hospital of Hebei Engineering University, Handan, China, First Hospital of Qinhuangdao, Qinhuangdao, China, Qinhuangdao Maternal and Child Health Hospital, Qinhuangdao, China,
Abstract
Characterization of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer and glioblastoma multiforme.Org: BioTheryX, San Diego State University Department of Biology, San Diego, CA, CanSino Biologics,
Abstract
A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer.Org: Memorial Sloan Kettering Cancer Center, Interventional Radiology Service,
Abstract
Relationship of adaptive subtyping and tumour heterogeneity of treatment response to neoadjuvant therapy in hormone receptor–positive HER2-negative early breast cancer: PENELOPE-B.Org: GBG Forschungs GmbH, German Breast Group, Helios Klinikum Berlin-Buch, Roswell Park Comprehensive Cancer Center, Penn Medicine Abramson Cancer Center,
Abstract
I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).Org: University of California, San Francisco, Mayo Clinic, University of Chicago Medical Center, Chicago, IL, Winship Cancer Institute of Emory University, Hunstman Cancer Institute at the University of Utah,
Abstract
Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation.Org: Pangaea Oncology, Breast Oncology Institute, Sermonix Pharmaceuticals, Mayo Clinic, Medical Oncology,
Abstract
Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.Org: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Breast Surgery, Jiangxi Cancer Hospital, Nanchang, China, Hunan Cancer Hospital, Changsha, China, Breast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, China,
Abstract
On-treatment (tx) dynamic circulating tumor DNA changes (∆ctDNA) associated with progression-free survival (PFS) and overall survival (OS) of patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA-3 (ML-3).Org: BC Cancer - Vancouver Centre, Novartis Pharmaceuticals Corporation, Novartis Institutes for BioMedical Research, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori Regina Elena,
Abstract
Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.Org: Winship Cancer Institute of Emory University, IRCCS Ospedale San Raffaele, Sarah Cannon Research Institute/Tennessee Oncology, Lifespan Cancer Institute, Legorreta Cancer Center at Brown University,
Abstract
Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial.Org: Hospital del Mar, Barcelona, Spain, CIBERONC-ISCIII, Biovica International AB, Hospital Clínico Universitario de Valencia, INCLIVA-Biomedical Research Institute,
Abstract
Evaluating Ki67 and Oncotype DX Breast Recurrence Score during neoadjuvant treatment with letrozole/abemaciclib or chemotherapy in patients with highly proliferative HR+/HER2- breast cancer participating in the GEICAM CARABELA trial.Org: Spanish Breast Cancer Group, Málaga,
Abstract
Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase 1b/2 study.Org: Sarah Cannon Research Institute/Tennessee Oncology, Asan Medical Center, Samsung Medical Center, Menarini Group, Hospital Universitario 12 de Octubre,
Abstract
Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study.Org: Baylor University Medical Center, Texas Oncology, The US Oncology Network, International Breast Cancer Center (IBCC), Quironsalud Group,
Abstract
Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer (ABCSG-42/AFT-05/BIG-14-13).Org: Dana-Farber Cancer Institute, Mayo Clinic, Medical University of Vienna, Washington University School of Medicine, The University of Texas MD Anderson Cancer Center,
Abstract
Unveiling the cost-effectiveness of CDK4/6 inhibitors in treating patients with HR+/HER2- metastatic breast cancer: A closer look at nonmedication expenses.Org: UVA Comprehensive Cancer Center, University of Virginia, Charlottesville, VA, USA, Duke University Medical Center/Duke Cancer Institute,
Abstract
Symptom management through electronic patient-reported outcome (ePRO)-based intervention in patients with breast cancer treated with abemaciclib: Primary results from the LIBRA study, a phase II randomized controlled trial.Org: Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Keio University School of Medicine, Keio University School of Medicine General Surgery, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Department of Breast Medical Oncology, Japanese Foundation for Cancer Research,
Abstract
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Final results of the investigator-initiated phase II BEAVER trial.Org: Department of Laboratory Medicine and Pathobiology,
Abstract
Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium.Org: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, Northwestern Memorial Hospital, Chicago, IL, Chicago, IL, Il-Yang Pharmaceuticals, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,
Abstract
Efficacy and safety of neoadjuvant trastuzumab, pyrotinib, and dalpiciclib without chemotherapy in early-stage HR-negative/HER2-positive breast cancer: An open-label, single-arm phase II trial.Org: The First People's Hospital of Xiangtan City, Xiangtan, ShaoYang Central Hospital,
Abstract
Efficacy of fadraciclib (CYC065), a novel dual CDK2/9 inhibitor, on patient-derived models of colorectal cancer.Org: Cyclacel Pharmaceuticals Inc,
Abstract
Comparison of antitumor efficacy of first-line palbociclib, ribociclib, or abemaciclib in patients with HR+/HER2- aBC: Results of the multicenter, real-world, Italian study PALMARES-2.Org: IRCCS Policlinico S. Matteo, Dip Scienze Medico Chirurgiche Medicina, ICS Maugeri IRCCS, Ospedale di Mirano Dolo, ASST Fatebenefratelli Sacco,
Abstract
The analysis of prescribing CDK4/6 inhibitors for patients with breast cancer in real clinical practice.Org: City Clinical Oncology Dispensary, St. Petersburg City Clinical Oncology Dispensary, Saint Petersburg State University, Medical Faculty,
Abstract
(CDK) 4/6 inhibitors: An effective treatment for homologous recombination deficient (HRD) luminal breast cancers (BC)?Org: UNEB,
Abstract
The association of hormone receptor expression level and clinical efficacy of CDK4/6 inhibitor in hormone receptor-positive, HER2-negative metastatic breast cancer.Org: Department of Clinical Oncology, Queen Elizabeth Hospital, Queen Elizabeth Hospital, Hong Kong Sanatorium & Hospital,
Abstract
Frequency of dose reductions of abemaciclib in metastatic and early-stage hormone positive, HER2 negative breast cancer.Org: Scripps Clinic/Green Hospital, La Jolla, CA,
Abstract
Genomics to select treatment for patients (pts) with metastatic cancer: Final analysis of Molecular Tumor Board (MTB) evaluations in the ROME trial.Org: IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy, Department of Clinical and Molecular Medicine, Oncology Unit, Sant’ Andrea University Hospital, Sapienza University of Rome, Roma, Italy, Dipartimento di Eccellenza in Medicina Molecolare e Biotecnologie Mediche, Università Federico II, Napoli UOC PATOLOGIA CLINICA - Ospedale San Giovanni Addolorata, Roma, Rome, Italy, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy,
Abstract
The association between age, toxicity and outcomes of abemaciclib treatment in HR+/HER2- metastatic breast cancer.Org: Faculty of Medicine, University of Ljubljana,
Abstract
The impact of vitamin D levels on the progression-free survival of women with hormone receptor-positive, HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors.Org: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,
Abstract
Effect of neratinib on HER2 mRNA stability via hsa-miR-23a-5p and efficacy of CDK4/6 inhibitors in HER2-low breast cancer.Org: The Second Clinical College of Guangzhou University of Chinese Medicine,
Abstract
Efficacy and safety of abemaciclib in combination with endocrine therapy for HR+/HER2- advanced or metastatic breast cancer: A systematic review and meta-analysis.Org: Services Institute of Medical Sciences,
Abstract
Efficacy and safety of dalpiciclib, fulvestrant, and pyrotinib in HR+ HER2-low advanced breast cancer following cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors and aromatase inhibitors (AIs): A Bayesian optimal phase II trial.Org: First Hospital of China Medical University,
Abstract
HOPE: Harnessing olaparib, palbociclib, and endocrine therapy for BRCA1/2-associated HR+, HER2- metastatic breast cancer.Org: Penn Medicine Abramson Cancer Center, University of Pennsylvania, Abramson Cancer Center, Hospital of the University of Pennsylvania, Memorial Sloan Kettering Cancer Center,
Abstract
Real world experience with cyclin dependent kinase inhibitors in metastatic breast cancer from India.Org: Rajiv Gandi Cancer Institute & Research Centre,
Abstract
Clinical significance of circulating tumor DNA in neoadjuvant-treated HER2-negative luminal B breast cancer.Org: Genecast Biotechnology Co., Ltd, Beijing, China,
Abstract
Neoadjuvant dalpiciclib combined with aromatase inhibitors in stage I-III HER2 negative luminal B breast cancer (DANCER): Preliminary findings from an ongoing phase II study.Org: Genecast Precision Medical Diagnostic Laboratory, Wuxi Co., Ltd, Wuxi, China,
Abstract
Real-world comparison of the efficacy of three CDK4/6 inhibitors (CDK4/6i) in the first-line treatment of endocrine-sensitive advanced breast cancer (aBC): Single institution experience.Org: School of Medicine, University of Zagreb, Department of Pathology, University Hospital Center Zagreb, Department of Pathology, University Hospital for Tumors, Sestre Milosrdnice University Hospital Center,
Abstract
Early tumor response in first‐line palbociclib plus AI in Chinese women with HR+/HER2- advanced breast cancer: Primary analysis of a multicenter, prospective real-world study.Org: The Affiliated People's Hospital of Ningbo University, Medical School of Zhejiang University,
Abstract
Cognitive function in patients with HR+ advanced breast cancer treated with endocrine therapy with or without CDK4/6 inhibitors in the SONIA trial.Org: Psychosocial Research and Epidemiology, Netherlands Cancer Institute (Netherlands ),
Abstract
Alisertib in patients with extensive-stage small-cell lung cancer: The phase 2 ALISCA-Lung1 study.Org: Puma Biotechnology Inc.,
Abstract
The effects of anlotinib combined with chemotherapy following progression on cyclin-dependent kinase 4/6 inhibitor in hormone receptor-positive metastatic breast cancer.Org: Jiangsu Cancer Hospital, Nanjing, Jiangsu, China,
Abstract
Neoadjuvant adebrelimab plus dalpiciclib in HPV-negative locally advanced head and neck squamous cell carcinoma: A phase II clinical trial.Org: National Clinical Research Center for Oral Diseases, Department of Head and Neck Oncology Surgery,
Abstract
Real-world treatment outcomes in patients with HR+ HER2- advanced breast cancer treated with CDK4/6 inhibitors and endocrine therapy.Org: Military Institute of Medicine-National Research Institute, Department of Oncology, National Taiwan University Hospital, Department of Clinical Oncology, Queen Elizabeth Hospital, Breast Unit, Lower Silesian Oncology Centre,
Abstract
Optimization of surgical management of the axilla since MonarchE trial.Org: Georges François Leclerc Comprehensive Cancer Care Centre, Centre Georges François Leclerc, Centre Georges Francois Leclerc,
Abstract
Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: An overall survival update and long-term safety from the randomised, double-blind, placebo-controlled, phase 3 trial.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Harbin Medical University Cancer Hospital,
Abstract
First-in-human phase 1 study of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, West China Hospital, Sichuan University, Chengdu Origen Biotechnology, China National Biotec Group,
Abstract
Real-world (RW) elacestrant use patterns and therapeutic outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC).Org: Guardant Health, Inc., Guardant Health, Sarah Cannon Research Institute/Tennessee Oncology, Winship Cancer Institute of Emory University, Massachusetts General Hospital Cancer Center,
Abstract
Cancer outcomes from a real-world cohort of patients eligible for adjuvant CDK4/6 inhibitors but without genomic risk for chemotherapy: A GBECAM multicenter retrospective study.Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Hospital Moinhos de Vento, Sírio Libanês Hospital, Hospital Sírio-Libanês, A.C. Camargo Cancer Center,
Abstract
INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–), PIK3CA‑mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Winship Cancer Institute of Emory University, Seoul National University Hospital, IRCCS Ospedale San Raffaele,
Abstract
Preliminary results from a phase 1 study of AC699, an orally bioavailable chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer.Org: Compass Oncology/US Oncology Network, Accutar Biotechnology Inc.,
Abstract
GOG3069: Phase 2 study of alpelisib and fulvestrant for PIK3CA-mutated estrogen receptor (ER)-positive endometrioid endometrial cancers.Org: Kettering Health Cancer Center, St. Vincent Hospital and Health Care Centers, Legacy Good Samaritan Medical Center, University of Wisconsin-Madison School of Medicine and Public Health, The University of Cincinnati Cancer,
Abstract
Overall survival analysis of first line CDK4/6 inhibitors in a large real-world cohort of patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University,
Abstract
In silico design of novel multitarget small molecule inhibitors to treat PTEN-mutant endometrial carcinoma.Org: Molecular Targeted Therapeutics Laboratory,
Abstract
Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).Org: The Netherlands Cancer Institute, Erasmus MC Cancer Institute, Netherlands Comprehensive Cancer Organisation (IKNL), Erasmus School of Health Policy & Management, Spaarne Gasthuis,
Abstract
Clinico-molecular characteristics associated with outcomes in breast cancer patients treated with CDK4/6 inhibitors: Results from the AURORA Molecular Screening Initiative.Org: Université Libre de Bruxelles (ULB), Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium, Breast International Group, Brussels, Belgium, Dana-Farber Cancer Institute, Vall d’Hebron Institute of Oncology (VHIO),
Abstract
LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.Org: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Harbin Medical University Cancer Hospital, Harbin, China, Genor Biopharma Co., Ltd, Beijing, China, Genor Biopharma Co., Ltd., Beijing, China,
Abstract
Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: Primary results from the phase III NATALEE trial.Org: David Geffen School of Medicine at University of California Los Angeles, Moscow City Oncology Hospital No.62, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, National Taiwan University Hospital,
Abstract
Palbociclib in solid tumor patients with genomic alterations in the cyclin D-CDK4/6-INK4a-Rb pathway: Results from NCI-COG Pediatric MATCH trial Arm I (APEC1621I).Org: Department of Pediatrics, University of Colorado and Center for Cancer and Blood Disorders, Children’s Hospital Colorado, Aurora, CO, University of Michigan, Ann Arbor, MI, Mayo Clinic, Rochester, MN, Children's Oncology Group, Monrovia, CA, Univ of Southern California/Children's Oncology Group, Arcadia, CA, Texas Children's Cancer and Hematology Center, Houston, TX, St. Jude Children's Research Hospital, Memphis, TN, Seattle Children's Hospital, Seattle, WA, National Cancer Institute, Rockville, MD, Frederick National Laboratory for Cancer Research, Frederick, MD, Center for Biomedical Informatics & Information Technology, NCI, NIH, Bethesda, MD, MD Anderson Cancer Center, Houston, TX, Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, National Cancer Institute Center for Bioinformatics, Rockville, MD, Dana-Farber Cancer Institute, Boston, MA, Cancer Therapy Evaluation Program, NCI, Bethesda, MD, Texas Children's Cancer Center/Baylor College of Medicine, Houston, TX,
Abstract
Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial.Org: Royal Cancer Hospital, Heidelberg University, Department of Oncology, National Taiwan University Hospital, Asan Medical Center, Service de Oncología Médica,
Abstract
CANKADO PRO-React eHealth support in patients with HR+ HER2- metastatic breast cancer receiving palbociclib and endocrine therapy and the affect on time to deterioration of quality of life: Primary outcome analysis of the multicenter randomized PreCycle trial.Org: Breast Center, LMU University Hospital, Comprehensive Cancer Center Erlangen-EMN, Joint practice Wolfratshausen, Medical University of Brandenburg,
Abstract
First-line systemic treatment with palbociclib in women aged ≥70 years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program.Org: PACAN platform, Unité d'Oncogériatrie, Department of Geriatrics, Institut Paoli-Calmettes, Marseille, France, Institut Curie, Saint Cloud, France,
Abstract
Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).Org: Tennessee Oncology, PLLC, University General Hospital of Heraklion, Hospital de Cancer de Londrina, Baskent University Faculty of Medicine, Mater Adult Hospital Brisbane,
Abstract
Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC).Org: Dana-Farber Cancer Institute, Medical Faculty Mannheim, Pangaea Oncology, Queen Mary University of London, Centre Léon Bérard,
Abstract
A phase II trial of palbociclib combined to letrozole after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer: LACOG 1018.Org: Hospital São Lucas da PUCRS, Hospital Fêmina - Grupo Hospitalar Conceição, Brazilian Gynecologic Oncology Group (EVA), Latin American Cooperative Oncology Group (LACOG), Division of Clinical Research and Technological Development - Brazilian National Cancer Institute (INCA),
Abstract
Circulating tumor DNA (ctDNA) monitoring in patients with breast cancer receiving neoadjuvant palbociclib and endocrine therapy: A secondary analysis of the NeoRHEA phase 2 study.Org: Institut Jules Bordet, Université Libre de Bruxelles, Institut Jules Bordet and l’Université Libre de Bruxelles (U.L.B.), NeoGenomics Ltd, Jules Bordet Institute, Institut Jules Bordet and Université Libre de Bruxelles (U.L.B), Brussels, Belgium,
Abstract
A single-arm, phase 2 clinical trial of abemaciclib in adult patients with recurrent grade 3 oligodendroglioma.Org: Hospital of the University of Pennsylvania, University of Pennsylvania,
Abstract
Correlation of CDKN2A genomic alterations with tumor response to palbociclib given before chemoradiation therapy (CRT) to patients with human papillomavirus (HPV)-negative, locally advanced head and neck squamous-cell carcinoma (LA-HNSCC): A single-arm, phase 2 trial.Org: Washington University School of Medicine in St Louis, Washington University in Saint Louis Department of Biomedical Engineering, Department of Surgery, Brigham and Women's Hospital, Boston, MA, Washington University Siteman Cancer Center, St. Louis, MO, Washington University in St. Louis,
Abstract
Harnessing olaparib, palbociclib, and endocrine therapy: A phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA mutation-associated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HOPE).Org: University of Pennsylvania-Abramson Cancer Center, Philadelphia, PA, University of Pennsylvania, Hospital of the University of Pennsylvania, Univ of Pa,
Abstract
Endocrine therapy resistance (ETR) in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+, HER2– mBC): Prevalence, biomarker characteristics, and outcomes.Org: Dana-Farber Cancer Institute, Genentech, F. Hoffmann-La Roche Ltd, University Hospitals Seidman Cancer Center, Massachusetts General Hospital,
Abstract
Indirect treatment comparison of first-line CDK4/6-inhibitors in post-menopausal patients with HR+/HER2- metastatic breast cancer.Org: Yong Loo Lin School of Medicine, National University of Singapore (NUS), Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, National University Cancer Institute, Mediclinic City Hospital,
Abstract
Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors.Org: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, Toronto, ON, Canada,
Abstract
TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer.Org: University of Texas MD Anderson Cancer Center, Sunnybrook Odette Cancer Centre, University of Toronto, The Ottawa Hospital and University of Ottawa, Washington University School of Medicine in St Louis,
Abstract
Distribution and outcomes of HER2-low and HER2-zero metastatic breast cancer in Black and younger women.Org: UNC Lineberger Comprehensive Cancer Center/University of Milan, University of North Carolina at Chapel Hill, Department of Medicine, University of North Carolina at Chapel Hill, University of North Carolina/Lineberger Comprehensive Cancer Center, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC,
Abstract
Utility of Ki67 in guiding adjuvant abemaciclib therapy for patients with hormone receptor (HR)-positive, early breast cancer (EBC).Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Morningside-West, Icahn School of Medicine, Tisch Cancer Institute,
Abstract
A prospective, phase II, neoadjuvant clinical study based on chemotherapy sensitivity in hormone receptor–positive, HER2-negative breast cancer: FINEST study.Org: Fudan University Shanghai Cancer Center, Shanghai Cancer Center, Shanghai, China, Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shangai, China, Jiangsu Hengrui Pharmaceuticals Co., Ltd.,
Abstract
Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Guardant Health, Inc., Palo Alto, CA, Redwood City, CA,
Abstract
Discovery of CDK4/6 bifunctional degraders for ER+/HER2- breast cancer.Org: San Diego, CA, BioTheryX,
Abstract
ORACLE-RIPA study: A phase II, randomized, open-label, parallel-group study comparing the immune modulation effect of neoadjuvant ribociclib, palbociclib, and abemaciclib in early ER+/HER2- breast cancer.Org: National Taiwan University Hospital Yunlin Branch, National Taiwan University Cancer Center/Hospital,
Abstract
Comparative overall survival of patients in trials of CKD4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.Org: University of Toronto, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Centre Hospitalier Universitaire de Québec,
Abstract
BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.Org: Florida Cancer Specialists and Sarah Cannon Research Institute, Sarasota, FL, USA, Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital, Boston, MA, USA, Massachusetts General Hospital, Columbia University Irving Medical Center, New York, NY, USA, University of Virginia, Charlottesville, VA, USA,
Abstract
State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations.Org: Clinical Care Options, LLC, Reston, VA, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER+ metastatic breast cancer.Org: Memorial Sloan Kettering Cancer Center, START Midwest, Grand Rapids, MI, Valkyrie Clinical Trials, Inc, Stanford Hospital & Clinics, Virginia Cancer Specialists,
Abstract
evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC).Org: Dana-Farber Cancer Institute, UPMC Hillman Cancer Center, University of Pittsburgh Cancer Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Memorial Sloan Kettering Cancer Center,
Abstract
Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.Org: SOLTI Cancer Research Group, Ohio State University Comprehensive Cancer Center, Novartis Pharmaceuticals, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, University of North Carolina School of Medicine,
Abstract
Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM).Org: The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, University Hospitals Bristol and Weston NHS Foundation Trust, The Beatson Cancer Centre, Glasgow, United Kingdom, Mount Vernon Cancer Centre, University of Manchester and The Christie NHS Foundation Trust,
Abstract
Efficacy analysis of CDK4/6 inhibitors (CDKi) + endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC): Biomarker analysis including chemoendocrine score (CES) by CDKi type in SOLTI-1801_CDK-PREDICT study.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital 12 de Octubre, Hospital Clínic de Barcelona, IDIBAPS, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), SOLTI Breast Cancer Cooperative Group,
Abstract
A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer.Org: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Harbin Medical University Cancer Hospital, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital, Shenyang, China, Liaoning Cancer Hospital and Institute, Shenyang, China,
Abstract
BrUOG 387: Phase Ib investigator-initiated trial of a heat shock protein 90 inhibitor (HSP90i) combined with a CDK4/6i in advanced breast cancer progressing on CDK4/6i and in solid tumors with retinoblastoma (Rb)-deficiency (IND163592).Org: Legorreta Cancer Center at Brown University, Lifespan Health System, The Warren Alpert Medical School of Brown University, Rhode Island Hospital, Brown University - Lifespan Cancer Institute,
Abstract
A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.Org: Memorial Sloan Kettering Cancer Center, University of Texas MD Anderson Cancer Center, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Palbociclib + cetuximab versus cetuximab in patients with CDKN2A-altered, anti-PD-1 resistant, HPV-negative head and neck squamous cell carcinoma (HNSCC): A phase 3 trial.Org: Washington University School of Medicine in St Louis, Washington University Siteman Cancer Center, St. Louis, MO,
Abstract
INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–) PIK3CA‑mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Winship Cancer Center of Emory University, Seoul National University Hospital, Cancer Research Institute,
Abstract
CAPTOR-BC: Comprehensive analysis of spatial, temporal and molecular biomarkers predicting response and resistance to first-line treatment with ribociclib + ET in HR+, HER2- advanced breast cancer.Org: Erlangen University Hospital, Department of Gynecology and Obstetrics, TU Dresden, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China,
Abstract
Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: Safety, efficacy, and immune correlate data from a phase 2 study.Org: Department of Medicine, Duke University School of Medicine, Texas Oncology-Baylor Charles A. Sammons Cancer Center, PIH Health Whittier Hospital, Nebraska Hematology-Oncology P.C., Division of Hematology/Oncology, David Geffen School of Medicine at the University of California Los Angeles/Jonsson Comprehensive Cancer Center,
Abstract
Interim analyses (IA) of the giredestrant (G), G + abemaciclib (A), and G + ribociclib (R) arms in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2– LA/mBC).Org: Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, University of California Comprehensive Cancer Center, San Francisco, CA, Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), The Chaim Sheba Medical Center, Tel Aviv, Israel,
Abstract
Primary efficacy analyses of NeoRHEA, neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer.Org: Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Université Libre de Bruxelles, Academic Trials Promoting Team (ATPT), Institut Jules Bordet and l’Université Libre de Bruxelles (U.L.B.),
Abstract
A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).Org: David Geffen School of Medicine at UCLA, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, Stanford University, Stanford, CA, California Pacific Medical Center Research Institute, San Francisco, CA, Women's Health Integrated Research Center at Inova Health System, Annandale, VA, Women’s Health Integrated Research Center at Inova Health System, Department of Defense Gynecologic Cancer Center of Excellence, Annandale, VA, Stanford University Medical Center, Palo Alto, CA, Pingtung Veterans General Hospital, Pingtung, South Korea, Jonsson Comprehensive Cancer Center, Santa Monica, CA, Gustave Roussy Institute, Villejuif, France, Weill Cornell Medicine, New York, NY,
Abstract
Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET).Org: UT Health San Antonio, MD Anderson Cancer Center, Institut Curie, Saint Cloud, France, Universitaire Ziekenhuizen (UZ) - Leuven Cancer Institute, University Hospitals Seidman Cancer Center, Jean Perrin Cancer Centre,
Abstract
Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study.Org: CRO Aviano National Cancer Institute, IRCCS, Aviano, Italy, Dana-Farber Cancer Institute, Boston, MA, USA, Weill Cornell Medicine, New York, NY, Miami Cancer Institute, Baptist Health South Florida, Plantation, FL, Washington University School of Medicine, St. Louis, MO,
Abstract
Abemaciclib in recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) harboring CDKN2A loss, and/or CCND1 and/or CDK6 amplification: A phase II multicenter trial.Org: Centre Léon Bérard, Centre de Lutte Contre le Cancer Antoine Lacassagne, GINECO-Centre Jean Perrin, Clermont-Ferrand, France, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Hôpital Saint-André,
Abstract
HER2-low expression as a prognostic factor in patients treated with CDK4/6 inhibitors: A retrospective analysis.Org: Virgen del Rocio Hospital, Institute of Biomedicine of Seville (IBiS), CSIC, Universidad de Sevilla, Andalusian - Roche Network Mixed Alliance in Precision Medical Oncology,
Abstract
A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma.Org: Memorial Sloan Kettering Cancer Center, Sarcoma Medical Oncology Service,
Abstract
Anticancer–drug-induced interstitial lung disease (DIILD): With great power comes great responsibility.Org: Syneos Health, Morrisville, NC, NC Medical Research, Gurugram, Indiana University – Purdue University Indianapolis,
Abstract
Evaluation of palbociclib in combination with topotecan and cyclophosphamide in pediatric patients with recurrent or refractory neuroblastoma.Org: Children’s Hospital of Philadelphia, Abramson Cancer Center, University of Pennsylvania, Children's Hospital Los Angeles Department of Pediatrics, Department of Pediatrics & Adolescent Medicine, Queen Mary Hospital,
Abstract
Racial disparities in utilization of first line targeted therapies for metastatic breast cancer.Org: University of Pennsylvania, Department of Medicine (Hematology - Oncology Division), Perelman School of Medicine, University of Pennsylvania,
Abstract
Characterizing the tumor selectivity of oncolytic adenovirus ICVB-1042: Analysis of S-phase induction, viral replication, and cytolytic activity in human primary normal cell types.Org: IconOVir Bio, CellTx Consulting, LLC,
Abstract
Palbociclib, trastuzumab, pyrotinib and fulvestrant in patients with brain metastasis from ER/PR positive, HER-2 positive breast cancer: Report from an interim analysis of a multicenter, prospective study in China.Org: Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Sun Yat-sen University Cancer Center, Guangzhou, China, Affiliated cancer hospital of Guangxi Medical University, Guangxi, China,
Abstract
Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A).Org: Hospital Infantil Universitario Niño Jesús, Vall d'Hebron Barcelona Hospital Campus, National Cancer Center Hospital East, Kashiwa, Japan, Fondazione Policlinico Universitario A. Gemelli IRCCS, Phoenix Children's Hospital,
Abstract
Making sense of the dollars: Evaluation of financial toxicity in patients of breast medicine receiving oral chemotherapy at Roswell Park.Org: Roswell Park Comprehensive Cancer Center, The D'Youville University School of Pharmacy,
Abstract
BPI-16350, a novel promising CDK4/6 inhibitor for HR+/HER2- metastatic breast cancer (MBC): Results from a phase I study.Org: Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center, Shanghai, China, Gracell Biotechnologies, Ltd., Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The Third Hospital of Nanchang,
Abstract
Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.Org: Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands, Amsterdam UMC, Amsterdam, Netherlands, The Kinghorn Cancer Centre, St Vincent's Hospital, Darlinghurst, NSW, Australia, Department of medical oncology, Leiden University Medical Center, Leiden, Netherlands, NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia,
Abstract
Circulating tumor cells in patients with hormone receptor-positive, HER2-negative metastatic breast cancer receiving palbociclib with fulvestrant after progression on palbociclib with an aromatase inhibitor.Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University Bloomberg School of Public Health, RPS Hematology Oncology, Allegheny General Hospital, University of Michigan,
Abstract
Phase 1b/2 study of abemaciclib combined with chemoimmunotherapy in pediatric and young adult patients with relapsed/refractory neuroblastoma (JPCS Part C).Org: University of Minnesota Masonic Cancer Center, Minneapolis, MN, Riley Hospital for Children at Indiana University Health, The Warren Alpert Medical School of Brown University, David Geffen School of Medicine UCLA, Cohen Children's Medical Center,
Abstract
Cancer therapy-associated thrombosis: A patient- reported outcomes (PROs) analysis.Org: Care Across,
Abstract
Retrospective registry of patients with locally advanced/metastatic HR+/HER2− breast cancer treated in clinical practice in Andalusia.Org: Hospital de Jerez de la Frontera, Hospital Universitario San Cecilio, H. Virgen de las Nieves, Hospital Virgen Macarena, Hospital Nuestra Sra. De Valme,
Abstract
Effect of high immune-related gene expression on resistance to CDK4/6 inhibitors in advanced breast cancer.Org: Hospital Universitari Germans Trias i Pujol, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Catalan Institute of Oncology (ICO)-Badalona, B-ARGO (Badalona Applied Research Group in Oncology), IGTP (Health Research Institute Germans Trias i Pujol),
Abstract
Genomic landscape of CDK6 amplification and its potential prognostic value in adult-type diffuse gliomas.Org: Department of Neurosurgery, Peking Union Medical College Hospital, Beijing, China, Nanfang Hospital, Southern Medical University, State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,
Abstract
A randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in participants with relapsed or refractory Ewing sarcoma.Org: Eli Lilly and Company, Pediatric Oncology-Hematology Department, National Cancer Center Hospital East, Kashiwa, Japan, Hospital U i P La Fe, Peter MacCallum Cancer Centre, Melbourne, Australia,
Abstract
Evolution of breast cancer management in the Dominican Republic in the 21st century.Org: FUNDEONCAP, IOHP, Dominican Society of Oncology,
Abstract
Therapeutic potential of dual CDK12 and 13 inhibition in colorectal cancer.Org: UMass Chan Medical School, Duke University Medical Center,
Abstract
HR+/HER2- Breast cancer: The effect of online education on clinician knowledge, competence, and confidence in monitoring, mitigating toxicities, and developing patient-centric plans using a team-based approach.Org: Medscape Oncology, Carrollton, TX, Medscape LLC, New York, NY,
Abstract
Large versus limited molecular profiling panel screening program in patients with metastatic sarcoma: An exploratory subgroup analysis from the ProfiLER 02 trial.Org: Centre Léon-Bérard, Centre Léon Bérard, Centre Oscar Lambret, Institut Claudius Regaud/IUCT-Oncopole, Centre Eugène Marquis,
Abstract
The real-world modeling of benefits demonstrated in major clinical trials on 2 HR+/HER2− metastatic breast cancer treatment with CDK4/6 inhibitor in the US: PALOMA-2 and MONALEESA-3.Org: University of Virginia Health System, Duke University Medical Center / Duke Cancer Institute, University of Virginia, Charlottesville, VA, USA,
Abstract
Real world outcomes of trilaciclib in ES-SCLC.Org: Roswell Park Comprehensive Cancer Center, University at Buffalo School of Pharmacy and Pharmaceutical Sciences,
Abstract
Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary to in-transit and distant metastasis in acral melanoma.Org: Dana-Farber Cancer Institute, Universitatsklinikum Essen Klinik fur Dermatologie, Laboratory of Systems Pharmacology, Harvard Medical School, Department of Applied Computational Cancer Research,
Abstract
Clinical characteristics and outcome of PIK3CA mutated hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-), advanced breast cancer (BC) treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i): Real world data.Org: University Hospital Centre Zagreb, Clinical Hospital Centre Zagreb,
Abstract
Impact of use of CDK4/6i and neratinib among patients with HER2 +ve MBC: Results from a real world dataset.Org: Mediclinic City Hospital, TriNetX Europe,
Abstract
Comprehensive analysis of molecular characteristics, TMB, and MSI in Chinese patients with neuroendocrine neoplasms.Org: Department of Pathology, Shengjing Hospital of China Medical University, Shenyang, China, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China, The Medical Department, Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, China, Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, China,
Abstract
Cost-effectiveness of novel systemic therapies for advanced breast cancer: Global representativeness and influence of funding.Org: Instituto do Câncer do Estado de São Paulo (ICESP), University of São Paulo/ICESP, São Paulo, SP, Brazil, Sao Paulo State Cancer Institute (ICESP), São Paulo, Brazil,
Abstract
Efficacy of abemaciclib versus tucidinostat after progression on palbociclib in patients with HR+/HER2− MBC: A multicenter retrospective cohort study.Org: Fudan University Shanghai Cancer Center, Sun Yat-sen University Cancer Center Gansu Hospital, The First Hospital of China Medical University, Shenyang, China, Department of Medical Oncology, Liaoning Cancer Hospital & Institute, The First Affiliated Hospital with Nanjing Medical University,
Abstract
Real world evidence of systemic therapy in hormone receptor positive advanced breast cancer (HR+ ABC) in Australia: ARORA Registry.Org: Walter and Eliza Hall Institute of Medical Research, Eastern Health, Royal North Shore Hospital, Sydney, Australia, St Vincent's Private Hospital, The Mater Hospital Sydney,
Abstract
Phase 1/2 study of ARTS-021, a potent, oral administrated, selective CDK2 inhibitor, in advanced or metastatic solid tumors.Org: Allorion Therapeutics, Natick, MA, MaaT Pharma,
Abstract
Feasibility of treatment with another CDK4/6 inhibitor after severe ribociclib liver toxicity.Org: EHC, Morges, Switzerland, University Hospital 12 de Octubre, Institut Curie, Saint Cloud, France, Centre GF Leclercq,
Abstract
Comparative effectiveness of palbociclib plus aromatase inhibitor versus fulvestrant alone as initial endocrine therapy for HR+/HER2- advanced breast cancer in Chinese clinical practice: A real-world study.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China, National Cancer Centre Singapore,
Abstract
Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Results of fifth interim analysis (IA) from RIBANNA.Org: Onkologie Ravensburg, University Women’s Hospital, Paracelsus Medical University, Winicker Norimed GmbH, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China,
Abstract
Comparison of diversity across real-world evidence, randomized clinical trial, and Surveillance, Epidemiology, and End Results (SEER) data in patients with metastatic breast cancer.Org: Cardinal Health Specialty Solutions, Cardinal Health, Cardinal Health, LLC,
Abstract
Integrating radiation therapy with CDK4/6 inhibitors for breast cancer: A systematic review and meta-analysis of toxicity.Org: Azienda Ospedaliera Universitaria Careggi, University of Florence, AOUC, CyberKnife Center, Istituto Fiorentino di Cura e Assistenza (IFCA), The Royal Marsden NHS Foundation Trust and Institute of Cancer Research,
Drug
PalbociclibDrug
AbemaciclibDrug
PD0332991Drug
Ribociclib